Skip to content

Paracetamol Metabolism Research in Postoperative Hepatic Surgery

Paracetamol Metabolism Research in Postoperative Hepatic Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03297073
Acronym
PARAFOI
Enrollment
90
Registered
2017-09-29
Start date
2016-11-20
Completion date
2019-11-30
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Disease, Paracetamol Causing Adverse Effects in Therapeutic Use

Brief summary

The main objective of this study was to evaluate the 5-day kinetics of plasma paracetamol levels in postoperative major hepatic surgery (resection greater than or equal to three hepatic segments) compared with less extensive liver resection and hepatic re-intervention. The clearance of indocyanine green is a marker of hepatic perfusion but also of the proper hepatocyte functioning, if hemodynamic conditions are stable. Some patients may be operated on up to four or five times in the liver. Moreover, these patients probably present an increased risk of postoperative hepatocellular insufficiency due to a quantitative and qualitative decrease in their hepatic parenchyma. It is therefore interesting to evaluate the use of paracetamol in this situation.

Interventions

DRUGparacetamol

Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h. The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form

PROCEDUREhepatic surgery

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients requiring surgery for hepatic resection by initiation under chest or laparoscopic without hepatocellular insufficiency, * ASA score 1 to 3 (American Society of Anesthesiologists score ranging from 1 to 5 evaluating the preoperative health status of a patient), * Verification of the understanding of the protocol,

Exclusion criteria

* Patients classified ASA 4 or 5, * Allergy or intolerance to indocyanine green * Allergy or intolerance to paracetamol, * Taking of paracetamol the week before the intervention, * Patient less than 60 Kgs (because decrease of doses of paracetamol), * Emergency surgery, palliative surgery and surgical recovery, * Psychic disorder, * Contra-indication to a treatment used during the study, * incapable major, * Intellectual incapacity preventing proper understanding of the protocol, * Pregnant or nursing woman,

Design outcomes

Primary

MeasureTime frameDescription
Dosing and kinetics of paracetamolemiaduring the 5 post-operative daysthis determination of the plasma paracetamol dosage on D0 (H6: 6 hours after the end of the procedure) and D1 D2 D3 D4 D5 (samples taken at 6 am each day just before the injection of paracetamol whose administration hours will be 6h 12h 18h and midnight)

Secondary

MeasureTime frameDescription
Dosage of N-acetyl-cysteinyl paracetamol ( NAPQI)At Day 1, day 3, day 5 post operative
Percentage of patients with paracetamolemia greater than 60 mg / mLduring the 5 post-operative days60mj/ml = paracetamol toxicity threshold according to Prescott diagram to 6 hours
Plasma Disappearance Rate of indocyanine green (TDP-ICG) by LiMon®At Day 1, day 3, day 5 post operative
Rate of postoperative hepatocellular insufficiencyat day 5The postoperative hepatocellular insufficiency according to the 50/50 criteria (TP \<50% and bilirubinemia\> 50 μmol / L on the 5th day) according to the type of hepatic resection (with or without clamping, continuous or discontinuous, duration intervention).
Dosage of urinary metabolites of paracetamol (paracetamol sulphate, paracetamol glucuronide)At Day 1, day 3, day 5 post operative
Duration of hospitalization in perioperative intensive careat 30 days
Duration of total hospitalization.at 30 days
Mortalityat 30 days
Composite characteristics of surgery.at 30 daysCharacteristics of surgery: duration of intervention, numbers, duration and types of vascular clamping, detailed description of the type of liver resection performed, quantification of bleeding.
Occurrence of complications related to hepatic failureat day 5the complications related to hepatic failure not falling within the 50/50 criteria: jaundice, hepatic encephalopathy, coagulation disorders, ascites, cytolysis, cholestasis. Other medical and surgical. Duration of hospitalization in perioperative intensive care and duration of total hospitalization. Mortality at 30 days.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026